Elacestrant and the Promise of Oral SERDs

J Clin Oncol. 2022 Oct 1;40(28):3227-3229. doi: 10.1200/JCO.22.00841. Epub 2022 Jun 23.

Authors

Katherine G Sanchez^{1

2}, Julie R Nangia^{1

2

3}, Rachel Schiff^{1

2

3

4}, Mothaffar F Rimawi^{1

2

3}

Affiliations

¹ Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.
² Department of Medicine, Baylor College of Medicine, Houston, TX.
³ Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX.
⁴ Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX.

PMID: 35737918
DOI: 10.1200/JCO.22.00841

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Breast Neoplasms*
Estrogen Antagonists*
Female
Humans
Selective Estrogen Receptor Modulators
Tetrahydronaphthalenes

Substances

Estrogen Antagonists
Selective Estrogen Receptor Modulators
Tetrahydronaphthalenes
elacestrant